FDA再次拒绝将Intarcia公司的GLP-1受体激动剂皮下渗透泵ITCA 650,用于治疗2型糖尿病

2020-03-12 MedSci原创 MedSci原创

根据该公司的网站描述,ITCA 650有潜力为患者提供六个月的艾塞那肽,让患者无需每天或每周注射GLP-1。

Intarcia Therapeutics的胰高血糖素样肽-1(GLP-1)受体激动剂艾塞那肽的植入式皮下微量渗透泵ITCA 650,再次遭到FDA拒绝用于治疗2型糖尿病。

Intarcia表示对FDA的决定"感到非常失望",但"我们坚信ITCA 650作为治疗2型糖尿病的新疗法具有重要的潜力。" 根据该公司的网站描述,ITCA 650有潜力为患者提供六个月的艾塞那肽,让患者无需每天或每周注射GLP-1。

FDA最初于2017年拒绝了该皮下渗透泵。当时Intarcia表示,FDA已提供了有关"制造方面"的完整回复函,但指出不必"进行新的关键性试验"。该公司于去年10月重新提交了一份申请书。

Intarcia此次遭到FDA拒绝后没有提供完整的回复函详细信息,只是说:"我们期望与FDA开展会议,以了解情况并确定未来的前进方向。"

该公司在2014年将美国和日本以外的ITCA 650许可权转让给了Servier,交易价值可能超过10亿美元。随后,它公布了III期FREEDOM-2试验的主要结果,显示ITCA 650在降低2型糖尿病患者的HbA1c和体重方面均优于默克公司的DPP-4抑制剂Januvia(西格列汀)。

原始出处:

https://www.firstwordpharma.com/node/1707394?tsid=28&region_id=6

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1685354, encodeId=0cde1685354c8, content=<a href='/topic/show?id=66011e19807' target=_blank style='color:#2F92EE;'>#TCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17198, encryptionId=66011e19807, topicName=TCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766728143581, createdName=paperyu, createdTime=Mon Nov 30 23:31:10 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795294, encodeId=81981e95294e5, content=<a href='/topic/show?id=33e61e132a8' target=_blank style='color:#2F92EE;'>#TARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17132, encryptionId=33e61e132a8, topicName=TARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed Aug 19 10:31:10 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294035, encodeId=5760129403523, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422746, encodeId=d7f11422e46c9, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627812, encodeId=fce8162e81247, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043001, encodeId=848910430011e, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Mar 12 18:31:10 CST 2020, time=2020-03-12, status=1, ipAttribution=)]
    2020-11-30 paperyu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1685354, encodeId=0cde1685354c8, content=<a href='/topic/show?id=66011e19807' target=_blank style='color:#2F92EE;'>#TCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17198, encryptionId=66011e19807, topicName=TCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766728143581, createdName=paperyu, createdTime=Mon Nov 30 23:31:10 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795294, encodeId=81981e95294e5, content=<a href='/topic/show?id=33e61e132a8' target=_blank style='color:#2F92EE;'>#TARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17132, encryptionId=33e61e132a8, topicName=TARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed Aug 19 10:31:10 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294035, encodeId=5760129403523, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422746, encodeId=d7f11422e46c9, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627812, encodeId=fce8162e81247, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043001, encodeId=848910430011e, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Mar 12 18:31:10 CST 2020, time=2020-03-12, status=1, ipAttribution=)]
    2020-08-19 chenlianhui
  3. [GetPortalCommentsPageByObjectIdResponse(id=1685354, encodeId=0cde1685354c8, content=<a href='/topic/show?id=66011e19807' target=_blank style='color:#2F92EE;'>#TCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17198, encryptionId=66011e19807, topicName=TCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766728143581, createdName=paperyu, createdTime=Mon Nov 30 23:31:10 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795294, encodeId=81981e95294e5, content=<a href='/topic/show?id=33e61e132a8' target=_blank style='color:#2F92EE;'>#TARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17132, encryptionId=33e61e132a8, topicName=TARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed Aug 19 10:31:10 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294035, encodeId=5760129403523, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422746, encodeId=d7f11422e46c9, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627812, encodeId=fce8162e81247, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043001, encodeId=848910430011e, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Mar 12 18:31:10 CST 2020, time=2020-03-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1685354, encodeId=0cde1685354c8, content=<a href='/topic/show?id=66011e19807' target=_blank style='color:#2F92EE;'>#TCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17198, encryptionId=66011e19807, topicName=TCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766728143581, createdName=paperyu, createdTime=Mon Nov 30 23:31:10 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795294, encodeId=81981e95294e5, content=<a href='/topic/show?id=33e61e132a8' target=_blank style='color:#2F92EE;'>#TARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17132, encryptionId=33e61e132a8, topicName=TARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed Aug 19 10:31:10 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294035, encodeId=5760129403523, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422746, encodeId=d7f11422e46c9, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627812, encodeId=fce8162e81247, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043001, encodeId=848910430011e, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Mar 12 18:31:10 CST 2020, time=2020-03-12, status=1, ipAttribution=)]
    2020-03-14 yibei
  5. [GetPortalCommentsPageByObjectIdResponse(id=1685354, encodeId=0cde1685354c8, content=<a href='/topic/show?id=66011e19807' target=_blank style='color:#2F92EE;'>#TCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17198, encryptionId=66011e19807, topicName=TCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766728143581, createdName=paperyu, createdTime=Mon Nov 30 23:31:10 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795294, encodeId=81981e95294e5, content=<a href='/topic/show?id=33e61e132a8' target=_blank style='color:#2F92EE;'>#TARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17132, encryptionId=33e61e132a8, topicName=TARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed Aug 19 10:31:10 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294035, encodeId=5760129403523, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422746, encodeId=d7f11422e46c9, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627812, encodeId=fce8162e81247, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043001, encodeId=848910430011e, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Mar 12 18:31:10 CST 2020, time=2020-03-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1685354, encodeId=0cde1685354c8, content=<a href='/topic/show?id=66011e19807' target=_blank style='color:#2F92EE;'>#TCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17198, encryptionId=66011e19807, topicName=TCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766728143581, createdName=paperyu, createdTime=Mon Nov 30 23:31:10 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795294, encodeId=81981e95294e5, content=<a href='/topic/show?id=33e61e132a8' target=_blank style='color:#2F92EE;'>#TARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17132, encryptionId=33e61e132a8, topicName=TARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed Aug 19 10:31:10 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294035, encodeId=5760129403523, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422746, encodeId=d7f11422e46c9, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627812, encodeId=fce8162e81247, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sat Mar 14 06:31:10 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043001, encodeId=848910430011e, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Mar 12 18:31:10 CST 2020, time=2020-03-12, status=1, ipAttribution=)]
    2020-03-12 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Diabetologia:为什么在小鼠中测量胰高血糖素样肽-1是如此困难?

在人类中,胰高血糖素样肽-1(GLP-1)被二肽基肽酶-4快速降解成相对稳定的代谢物GLP-1(9-36)NH 2,从而可可对GLP-1分泌情况进行测定。然而,关于GLP-1代谢物在小鼠中的动力学知之甚少。近日,国际杂志 《Diabetologia》上在线发表一项关于在小鼠中测量胰高血糖素样肽-1的研究。研究人员假设GLP-1代谢物在该物种中通过中性肽链内切酶(NEP [s])快速降解。

Lancet:索马鲁肽减肥效果显著

研究认为索马鲁肽具有显著的减肥效果

Hypertension:胰高血糖素样肽-1与动态血压呈线性相关

瑞士一项研究表明,血浆胰高血糖素样肽-1水平与收缩压和舒张压水平均具有显著相关性。论文12月1日在线发表于《高血压》(Hypertension)。 此项研究共纳入1479例年龄为25~41岁的健康成人受试者,并利用高敏方法测定了空腹血浆胰高血糖素样肽-1水平和动态血压。评估血浆胰高血糖素样肽-1与血压指标的相关性。受试者中位年龄为38岁。 结果显示,胰高血糖素样肽-1由低到高各四分

Redox Biol:从"缺氧"窥看人类"肌肉减少症"

肌肉减少症是指骨骼肌的不自主丧失,是人类机体走向衰退的重要标志,非常容易引起骨折以及关节损伤等问题,还会影响器官功能,可能会引发心脏和肺部衰竭,甚至死亡。有学者提出其与缺氧信号改变,氧化应激,脂肪因子和炎症介质相关,但其机制尚不完全明确。有报道表明,暴露于高原缺氧环境下,肌肉减少症也会出现。

Cell子刊综述总结肠分泌激素GLP-1参与的心血管生物学

胰高血糖素样肽-1(GLP-1)是一种主要由肠道内分泌细胞产生的激素,能够通过调节胰岛激素分泌、胃肠蠕动和食物摄取控制葡萄糖代谢和能量平衡,因此许多研究团队和药企公司都在努力开发GLP-1受体激动剂用以治疗糖尿病和肥胖。除此之外,还有许多研究表明GLP-1可以作用于免疫系统抑制炎症,多个组织的GLP-1R信号途径能够影响心血管功能健康和疾病发生。   近日来自加拿大多伦多

JCEM:孕期糖尿病对其后代代谢的影响

孕妇孕期糖尿病会增加其及后代远期发生2型糖尿病(T2DM)和其他代谢综合征发病风险,而T2DM发病与肠促胰岛素、胰高血糖素样肽-1(GLP-1)、葡萄糖依赖性促胰岛素多肽(GIP)、高血糖素症等有关。